Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) rose 7% on Wednesday . The company traded as high as $13.90 and last traded at $13.90, with a volume of 171,285 shares. The stock had previously closed at $12.99.

Several research firms have issued reports on ADMS. Noble Financial began coverage on Adamas Pharmaceuticals in a report on Friday, June 17th. They issued a “buy” rating and a $25.00 price target on the stock. Mizuho reaffirmed a “buy” rating on shares of Adamas Pharmaceuticals in a report on Thursday, June 23rd. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Adamas Pharmaceuticals in a report on Wednesday, June 22nd. JMP Securities reaffirmed a “buy” rating on shares of Adamas Pharmaceuticals in a report on Wednesday, June 15th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $44.00 price target on shares of Adamas Pharmaceuticals in a report on Tuesday, June 14th. Two research analysts have rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $32.00.

The company’s 50-day moving average is $14.22 and its 200-day moving average is $15.29. The company’s market cap is $330.47 million.

A hedge fund recently bought a new stake in Adamas Pharmaceuticals stock. Ameriprise Financial Inc. purchased a new position in Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 64,978 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,840,000. Ameriprise Financial Inc. owned 0.35% of Adamas Pharmaceuticals at the end of the most recent reporting period.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.